Related Experiment Video
Updated: Sep 12, 2025
Detection of Rare Mutations in CtDNA Using Next Generation Sequencing
Published on: August 24, 2017
Unraveling the Potential of ctDNA in Precision Medicine for Breast Cancer
Juscelino Carvalho de Azevedo Junior1, Fernanda Jardim da Silva1, Anna Carolina Lima Rodrigues2
1Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém, Pará, Brazil.
Abstract:
Circulating tumor DNA has emerged as a minimally invasive and dynamic tool for providing real-time genetic insights into solid tumors, including breast cancer. Circulating tumor DNA is released into the bloodstream through apoptosis, necrosis, or active secretion, and it reflects tumor heterogeneity, which continues to be a major challenge in breast cancer treatment. Advances in high-sensitivity technologies, such as next-generation sequencing and digital polymerase chain reaction, have enabled the detection of key genetic alterations, offering applications in early diagnosis, monitoring minimal residual disease, identifying drug resistance mechanisms, and predicting relapse. Some circulating tumor DNA-based tests have already received regulatory approval for clinical use in patients with breast cancer, and additional studies are underway to expand their applicability. However, low concentrations of circulating tumor DNA and the necessity for standardization across different platforms remain a challenge for the expanded application. In this review, we present an overview of the genetic variants detected in circulating tumor DNA from patients with breast cancer, emphasizing their potential utility in guiding personalized therapeutic strategies and predicting treatment responses across the diverse molecular subtypes of the disease.
Insights
Circulating tumor DNA (ctDNA) offers real-time genetic insights into breast cancer, aiding diagnosis and treatment monitoring. Despite challenges like low concentrations, ctDNA analysis is crucial for personalized therapy and predicting patient outcomes.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Circulating tumor DNA (ctDNA) provides a non-invasive window into tumor biology.
- Tumor heterogeneity in breast cancer presents significant treatment challenges.
- ctDNA reflects real-time genetic information from solid tumors, including breast cancer.
Purpose of the Study:
- To review genetic variants detected in ctDNA from breast cancer patients.
- To highlight the utility of ctDNA in guiding personalized therapeutic strategies.
- To discuss ctDNA's role in predicting treatment responses across breast cancer subtypes.
Main Methods:
- Review of current literature on ctDNA analysis in breast cancer.
- Discussion of high-sensitivity detection technologies (e.g., next-generation sequencing, digital PCR).
- Analysis of applications including early diagnosis, MRD monitoring, resistance detection, and relapse prediction.
Main Results:
- ctDNA analysis enables detection of key genetic alterations in breast cancer.
- Approved ctDNA-based tests are available, with ongoing research for broader clinical use.
- Challenges include low ctDNA concentrations and the need for platform standardization.
Conclusions:
- ctDNA is a dynamic tool for real-time genetic insights in breast cancer.
- ctDNA analysis supports personalized treatment strategies and outcome prediction.
- Further standardization and technological advancements will expand ctDNA's clinical utility.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...